Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

Abstract

OBJECTIVEAcute, short-term hyperglycemia enhances high shear stress–induced platelet activation in type 2 diabetes. Several observations suggest that platelets in type 2 diabetes are resistant to inhibition by aspirin. Our aim was to assess comparatively the effect of aspirin, a nitric oxide–donating agent (NCX 4016), their combination, or placebo on platelet activation induced by acute hyperglycemia in type 2 diabetes.RESEARCH DESIGN AND METHODSIn a double-blind, placebo-controlled, randomized trial, 40 type 2 diabetic patients were allocated to 100 mg aspirin once daily, 800 mg NCX 4016 b.i.d., both of them, or placebo for 15 days. On day 15, 1 h after the morning dose, a 4-h hyperglycemic clamp (plasma glucose 13.9 mmol/l) was performed, and blood samples were collected before and immediately after it for platelet activation and cyclooxygenase-1 (COX-1) inhibition studies.RESULTSAcute hyperglycemia enhanced shear stress–induced platelet activation in placebo-treated patients (basal closure time 63 ± 7.1 s, after hyperglycemia 49.5 ± 1.4 s, −13.5 ± 6.3 s, P < 0.048). Pretreatment with aspirin, despite full inhibition of platelet COX-1, did not prevent it (−12.7 ± 6.9 s, NS vs. placebo). On the contrary, pretreatment with the NO donor NCX 4016, alone or in combination with aspirin, suppressed platelet activation induced by acute hyperglycemia (NCX 4016 +10.5 ± 8.3 s; NCX 4016 plus aspirin: +12.0 ± 10.7 s, P < 0.05 vs. placebo for both). Other parameters of shear stress–dependent platelet activation were also more inhibited by NCX 4016 than by aspirin, despite lesser inhibition of COX-1.CONCLUSIONSAcute hyperglycemia-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it. Therapeutic approaches aiming at a wider platelet inhibitory action than that exerted by aspirin may prove useful in patients with type 2 diabetes.

Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes

“…This is associated with increased muscle catabolism causing the observed rise in plasma amino acids and elevated glucocorticoid levels. Last, the increase in plasma O-phosphotyrosine might relate to elevated platelet activation as a result of the hyperglycaemic state [26,27]. Most interestingly, phosphotyrosine appeared in the same cluster with glucose and glyoxylate (see ESM Table 3).…”

Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets

“…The excessive activation and aggregation of platelets leads to exaggerated thrombus formation456. Consistent with this, platelet hyperaggregability appears to be involved in the pathogenesis of enhanced arterial thrombosis in DM257. Importantly, platelets contain mRNAs and mRNA splicing machinery and translate mRNA into proteins relevant to haemostasis and inflammation89.…”

A clinical cardiology perspective of thrombophilias

“…The inhibitory response of aspirin is attenuated in patients with diabetes [106] even among those with short periods of hyperglycemia [107]. The response to clopidogrel is also attenuated, with high on-treatment platelet reactivity in patients with coronary artery disease and concomitant renal insufficiency [108].…”